<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have previously shown that NS-7 [4-(4-fluorophenyl)-2-<z:chebi fb="36" ids="29309">methyl</z:chebi>-6-(5-piperidinopentyloxy)<z:chebi fb="0" ids="16898">pyrimidine</z:chebi> <z:chebi fb="16" ids="36807">hydrochloride</z:chebi>] reduces the size of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> measured by 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> staining at 48 h after permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in rats </plain></SENT>
<SENT sid="1" pm="."><plain>To determine whether NS-7 improves the pathological and <z:hpo ids='HP_0000708'>behavioral changes</z:hpo> at the <z:hpo ids='HP_0011010'>chronic</z:hpo> stage of MCAO, the effect of this compound on the <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> as well as the neurological and <z:hpo ids='HP_0100543'>cognitive impairments</z:hpo> was investigated 7 days after MCAO </plain></SENT>
<SENT sid="2" pm="."><plain>Single or five daily injections of NS-7 (0.125-0.5 mg/kg, i.v.) significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and improved the neuronal dysfunction including the hind leg <z:hpo ids='HP_0003470'>paralysis</z:hpo>, walking disability and motor <z:hpo ids='HP_0002311'>incoordination</z:hpo>, and the deficit of passive avoidance task, although the neuroprotective efficacy was not different among these dosing regimens </plain></SENT>
<SENT sid="3" pm="."><plain>On the other hand, the effects of single versus repeated injections of NS-7 at 0.1 or 0.2 mg/kg on the neurological symptoms were compared at 4 weeks after MCAO </plain></SENT>
<SENT sid="4" pm="."><plain>At a lower dose, repeated but not single injection of NS-7 significantly improved the neurological symptoms, although the single injection was effective at a higher dose </plain></SENT>
<SENT sid="5" pm="."><plain>From these findings, it is suggested that NS-7 reverses the behavioral and <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive dysfunction</z:e> observed at the <z:hpo ids='HP_0011010'>chronic</z:hpo> stage of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> by suppressing the <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
</text></document>